This RFI seeks industry capabilities for developing, testing, and manufacturing a ruggedized, MIL-standard-compliant device to deliver the drug nalmefene via both inhalation/intranasal and intramuscular routes for prophylactic and therapeutic use. The goal is to identify innovative solutions that can integrate both purposes into a single device capable of eventual FDA approval as both a product and a medical device. Responses, including white papers and technical insights, are requested by 12:00 PM ET on Friday, 3 April 2026. Submissions should detail design feasibility, operational readiness, sustainment strategies, estimated timelines, scalability, and cost drivers.